Profile image
Story Views

Last Hour:
Last 24 Hours:

Idiopathic Pulmonary Fibrosis Therapeutics Industry Report H2 2016 – Latest News and Press Releases

Thursday, November 17, 2016 3:07
% of readers think this story is Fact. Add your two cents.

Latest Idiopathic Pulmonary Fibrosis Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Idiopathic Pulmonary Fibrosis therapeutics industry report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects.

Browse more detail information about Idiopathic Pulmonary Fibrosis market report at:

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2016:

  • AdAlta Pty Ltd.
  • Aeolus Pharmaceuticals, Inc.
  • Afferent Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals Inc
  • ARMO Biosciences, Inc.
  • Asahi Kasei Pharma Corp.
  • Biogen Inc
  • Bioneer Corporation
  • BiOrion Technologies B.V.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chrysalis Pharma SAS
  • Compugen Ltd.
  • Cynata Therapeutics Limited
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • FibroStatin SL

And Others

Get a PDF Sample of Idiopathic Pulmonary Fibrosis Market Research Report at:

Key Topics Covered:
2.Idiopathic Pulmonary Fibrosis Overview
3.Idiopathic Pulmonary Fibrosis Therapeutics Development
4.Pipeline Products for Idiopathic Pulmonary Fibrosis – Overview
5.Pipeline Products for Idiopathic Pulmonary Fibrosis – Comparative Analysis
6.Idiopathic Pulmonary Fibrosis – Therapeutics under Development by Companies
7.Idiopathic Pulmonary Fibrosis – Therapeutics under Investigation by Universities/Institutes
8.Idiopathic Pulmonary Fibrosis Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Idiopathic Pulmonary Fibrosis – Products under Development by Companies
13.Idiopathic Pulmonary Fibrosis – Products under Investigation by Universities/Institutes
14.Idiopathic Pulmonary Fibrosis – Companies Involved in Therapeutics Development
15.Idiopathic Pulmonary Fibrosis Drug Profiles
16.Idiopathic Pulmonary Fibrosis Dormant Projects
17.Idiopathic Pulmonary Fibrosis Discontinued Products
18.Idiopathic Pulmonary Fibrosis Featured News & Press Releases
And Continue…

Get Discount on Idiopathic Pulmonary Fibrosis Market Research Report at:

This research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email –

We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.